<DOC>
	<DOC>NCT02325830</DOC>
	<brief_summary>The objective of this prospective, multi-center, randomized, double-blind trial is to assess the safety and efficacy of the CARILLON Mitral Contour System in treating functional mitral regurgitation (FMR) associated with heart failure, compared to a randomized Control group which is medically managed according to heart failure guidelines.</brief_summary>
	<brief_title>CARILLON Mitral Contour System® for Reducing Functional Mitral Regurgitation</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Diagnosis of dilated ischemic or nonischemic cardiomyopathy Functional Mitral Regurgitation: 2+ (Moderate), 3+ (Moderate/Severe), or 4+ (Severe) New York Heart Association (NYHA) II, III, or IV Six Minute Walk distance of at least 150 meters and no farther than 450 meters Left Ventricular Ejection Fraction ≤ 50 % LV end diastolic dimension (LVEDD) &gt;55mm or LVEDD/Body Surface Area (BSA) &gt; 3.0cm/m2 Stable heart failure medication regimen for at least three (3) months prior to index procedure Hospitalization in past three (3) months due to myocardial infarction, coronary artery bypass graft surgery, and/or unstable angina Hospitalization in the past 30 days for coronary angioplasty or stent placement Subjects expected to require any cardiac surgery within one (1) year Subjects expected to require any percutaneous coronary intervention within 30 days of enrollment Preexisting device (e.g., pacing lead) in coronary sinus (CS) / great cardiac vein (GCV), or anticipated need for CRT within twelve (12) months Presence of a coronary artery stent under the CS / GCV in the implant target zone Presence of left atrial appendage (LAA) clot. Presence of primary renal dysfunction or significantly compromised renal function as reflected by a serum creatinine &gt; 2.2 mg/dL OR eGFR &lt; 30 ml/min Inability to undertake a sixminute walk test due to physical restrictions/limitations Chronic severe pathology limiting survival to less than 12months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Functional mitral regurgitation</keyword>
	<keyword>Secondary mitral regurgitation</keyword>
	<keyword>Percutaneous mitral repair</keyword>
</DOC>